Skip to main content
NCBI home page
Journal of Clinical Pathology. Supplement (Royal College of Pathologists) logoLink to Journal of Clinical Pathology. Supplement (Royal College of Pathologists)
. 1980;14:35–40.

Basis of antifibrinolytic therapy

CRM Prentice 1
PMCID: PMC1347103  PMID: 6159375

Full text

PDF
35

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALKJAERSIG N., FLETCHER A. P., SHERRY S. xi-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem. 1959 Apr;234(4):832–837. [PubMed] [Google Scholar]
  2. ANDERSSON L., NILSSON I. M. Effect of 6-amino-n-caproic acid (6-ACA) on fibrinolysis and bleeding conditions in prostatic disease. Acta Chir Scand. 1961 May;121:291–298. [PubMed] [Google Scholar]
  3. Basu H. K. Fibrinolysis and abruptio placentae. J Obstet Gynaecol Br Commonw. 1969 Jun;76(6):481–496. doi: 10.1111/j.1471-0528.1969.tb05868.x. [DOI] [PubMed] [Google Scholar]
  4. Chauvet J., Acher R. The reactive site of the basic trypsin in hibitor of pancreas. Role of lysine 15. J Biol Chem. 1967 Sep 25;242(18):4274–4275. [PubMed] [Google Scholar]
  5. Claeys H., Vermylen J. Physico-chemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid. Biochim Biophys Acta. 1974 Apr 11;342(2):351–359. doi: 10.1016/0005-2795(74)90090-7. [DOI] [PubMed] [Google Scholar]
  6. DUBBER A. H., MCNICOL G. P., DOUGLAS A. S. AMINO METHYL CYCLOHEXANE CARBOXYLIC ACID (AMCHA), A NEW SYNTHETIC FIBRINOLYTIC INHIBITOR. Br J Haematol. 1965 Mar;11:237–245. doi: 10.1111/j.1365-2141.1965.tb06583.x. [DOI] [PubMed] [Google Scholar]
  7. DUBBER A. H., MCNICOL G. P., DOUGLAS A. S., MELANDER B. SOME PROPERTIES OF THE ANTIFIBRINOLYTICALLY ACTIVE ISOMER OF AMINO-METHYLCYCLOHEXANE CARBOXYLIC ACID. Lancet. 1964 Dec 19;2(7373):1317–1319. doi: 10.1016/s0140-6736(64)91108-0. [DOI] [PubMed] [Google Scholar]
  8. Davidson J. F., McNicol G. P., Frank G. L., Anderson T. J., Douglas A. S. Plasminogen-activator-producing tumour. Br Med J. 1969 Jan 11;1(5636):88–91. doi: 10.1136/bmj.1.5636.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dubber A. H., McNicol G. P., Uttley D., Douglas A. S. In vitro and in vivo studies with trasylol, an anticoagulant and a fibrinolytic inhibitor. Br J Haematol. 1968 Jan;14(1):31–49. doi: 10.1111/j.1365-2141.1968.tb01470.x. [DOI] [PubMed] [Google Scholar]
  10. Forbes C. D., Barr R. D., Reid G., Thomson C., Prentice C. R., McNicol G. P., Douglas A. S. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. Br Med J. 1972 May 6;2(5809):311–313. doi: 10.1136/bmj.2.5809.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. GORDON A. M., MCNICOL G. P., DUBBER A. H., MCDONALD G. A., DOUGLAS A. S. CLINICAL TRIAL OF EPSILON-AMINOCAPROIC ACID IN SEVERE HAEMOPHILIA. Br Med J. 1965 Jun 26;1(5451):1632–1635. doi: 10.1136/bmj.1.5451.1632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gaffney P. J., Brasher M. Subunit structure of the plasmin-induced degradation products of crosslinked fibrin. Biochim Biophys Acta. 1973 Jan 25;295(1):308–313. doi: 10.1016/0005-2795(73)90098-6. [DOI] [PubMed] [Google Scholar]
  13. Klöcking H. P., Markwardt F. Tierexperimentelle Verfahren zur Testung von Fibrinolytika und Antifibrinolytika. Folia Haematol Int Mag Klin Morphol Blutforsch. 1969;92(1):84–89. [PubMed] [Google Scholar]
  14. Landmann H. Studies on the mechanism of action of synthetic antifibrinolytics. A comparison with the action of derivatives of benzamidine on the fibrinolytic process. Thromb Diath Haemorrh. 1973 May 10;29(2):253–275. [PubMed] [Google Scholar]
  15. Markwardt F., Richter M. Zur Standardisierung des Proteaseninhibitors aus Rinderorganen. Pharmazie. 1969 Oct;24(10):620–622. [PubMed] [Google Scholar]
  16. Melander B., Gliniecki G., Granstrand B., Hanshoff G. Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). Acta Pharmacol Toxicol (Copenh) 1965;22(4):340–352. doi: 10.1111/j.1600-0773.1965.tb01829.x. [DOI] [PubMed] [Google Scholar]
  17. Merskey C., Johnson A. J., Kleiner G. J., Wohl H. The defibrination syndrome: clinical features and laboratory diagnosis. Br J Haematol. 1967 Jul;13(4):528–549. doi: 10.1111/j.1365-2141.1967.tb00762.x. [DOI] [PubMed] [Google Scholar]
  18. NAEYE R. L. Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocapproic acid. Blood. 1962 Jun;19:694–701. [PubMed] [Google Scholar]
  19. NILSSON I. M., BJORKMAN S. E., ANDERSSON L. Clinical experiences with 6-aminocaproic acid (6-ACA) as an antifibrinolytic agent. Acta Med Scand. 1961 Oct;170:487–509. doi: 10.1111/j.0954-6820.1961.tb00264.x. [DOI] [PubMed] [Google Scholar]
  20. Prentice C. R. Indications for antifibrinolytic therapy. Thromb Diath Haemorrh. 1975 Dec 15;34(3):634–643. [PubMed] [Google Scholar]
  21. Prentice C. R., Lindsay R. M., Barr R. D., Forbes C. D., Kennedy A. C., McNicol G. P., Douglas A. S. Renal complications in haemophilia and Christmas disease. Q J Med. 1971 Jan;40(157):47–61. [PubMed] [Google Scholar]
  22. Rickli E. E., Otavsky W. I. A new method of isolation and some properties of the heavy chain of human plasmin. Eur J Biochem. 1975 Nov 15;59(2):441–447. doi: 10.1111/j.1432-1033.1975.tb02472.x. [DOI] [PubMed] [Google Scholar]
  23. Rickli E. E., Otavsky W. I. Release of an N-terminal peptide from human plasminogen during activation with urokinase. Biochim Biophys Acta. 1973 Jan 25;295(1):381–384. doi: 10.1016/0005-2795(73)90106-2. [DOI] [PubMed] [Google Scholar]
  24. Robbins K. C., Summaria L., Hsieh B., Shah R. J. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem. 1967 May 25;242(10):2333–2342. [PubMed] [Google Scholar]
  25. Schwartz M. L., Pizzo S. V., Hill R. L., McKee P. A. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest. 1971 Jul;50(7):1506–1513. doi: 10.1172/JCI106636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Skoza L., Tse A. O., Semar M., Johnson A. J. Comparative activities of amino acid and polypeptide inhibitors on natural and synthetic substrates. Ann N Y Acad Sci. 1968 Jun 28;146(2):659–672. doi: 10.1111/j.1749-6632.1968.tb20324.x. [DOI] [PubMed] [Google Scholar]
  27. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids. Biochim Biophys Acta. 1975 May 30;393(1):55–65. doi: 10.1016/0005-2795(75)90216-0. [DOI] [PubMed] [Google Scholar]
  28. Thorsen S., Glas-Greenwalt P., Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh. 1972 Aug 31;28(1):65–74. [PubMed] [Google Scholar]
  29. Thorsen S., Kok P., Astrup T. Reversible and irreversible alterations of human plasminogen indicated by changes in susceptibility to plasminogen activators and in response to epsilon-aminocaproic acid. Thromb Diath Haemorrh. 1974 Dec 31;32(2-3):325–340. [PubMed] [Google Scholar]
  30. Walsh P. N., Rizza C. R., Matthews J. M., Eipe J., Kernoff P. B., Coles M. D., Bloom A. L., Kaufman B. M., Beck P., Hanan C. M. Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol. 1971 May;20(5):463–475. doi: 10.1111/j.1365-2141.1971.tb07061.x. [DOI] [PubMed] [Google Scholar]
  31. Walther P. J., Hill R. L., McKee P. A. The importance of the preactivation peptide in the two-stage mechanism of human plasminogen activation. J Biol Chem. 1975 Aug 10;250(15):5926–5933. [PubMed] [Google Scholar]
  32. Walton P. L. The hydrolysis of alpha-N-acetylglycyl-l-lysine methyl ester by urokinase. Biochim Biophys Acta. 1967 Jan 11;132(1):104–114. doi: 10.1016/0005-2744(67)90196-9. [DOI] [PubMed] [Google Scholar]
  33. Wiman B., Wallén P. Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. Eur J Biochem. 1973 Jul 2;36(1):25–31. doi: 10.1111/j.1432-1033.1973.tb02880.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology. Supplement (Royal College of Pathologists). are provided here courtesy of BMJ Publishing Group

RESOURCES